Navigation Links
Mpex Pharmaceuticals Announces Series D Financing of Up to $40 Million
Date:2/10/2009

SAN DIEGO, Feb. 10 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that it has completed a $27.5 million initial closing of a Series D financing led by Investor Growth Capital. Other participating investors include RiverVest Venture Partners, as well as existing investors SV Life Sciences, HBM BioVentures, Aberdare Ventures and Adams Street Partners. These investors have made commitments to additional closings that could bring the total Series D financing to $40.0 million.

Mpex's lead product candidate, MP-376, is a proprietary aerosol formulation of the antibiotic levofloxacin which is being developed as a maintenance therapy for the prevention of bacterial exacerbations in patients with chronic respiratory infections. MP-376 is currently being evaluated in ongoing Phase 2 clinical trials in patients with cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD).

"This new investment will enable us to complete the ongoing Phase 2 trials of MP-376 in both CF and COPD, as well as prepare for Phase 3 trials in these indications," said Daniel Burgess, President and Chief Executive Officer of Mpex. "We now have a very strong investor syndicate to help us advance these programs rapidly towards commercialization. We believe that this financing positions us well financially to achieve all of our development objectives for MP-376."

"MP-376 is a novel formulation of a proven antibiotic specifically designed for aerosol administration with a well-validated delivery system," said Sam Nickerson of Investor Growth Capital. "We are encouraged by the clinical data in CF patients to date and believe that if MP-376 is successful in reducing exacerbations in COPD patients, it will represent an important new therapy for this indication as well." In connection with the financing, Mr. Nickerson will join Mpex's board of directors.

CF is a hereditary disease affecting approximately 30,00
'/>"/>

SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Prism Pharmaceuticals Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
2. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
3. Pharmaceuticals sold in Sweden cause serious environmental harm in India
4. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
5. Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
6. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
8. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. ISTA Pharmaceuticals to Present at the 11th Annual BIO CEO & Investor Conference
10. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
11. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... one of the top public health concerns in the ... classified as obese as of 2012. As health problems ... taken to Twitter to discuss the problem. , A ... professor at the Brown School at Washington University in ... in tweets to track Twitter conversations about the issue ...
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) ... quality of life. Some patients have disturbed sleep/wake ... asleep, while other patients may be subject to ... extreme, PD patients may exhibit REM-sleep behavior disorder ... re-enactment, even before motor symptoms appear. A review ...
(Date:7/10/2014)... 10, 2014) A research review identifying the clinical ... first step in the process of developing evidence-based guidelines ... new report published by Neurosurgery , ... Surgeons . The journal is published by Lippincott ... Wolters Kluwer Health . , Based on analysis ...
(Date:7/10/2014)... Biomedical Research Institute (IDIBELL) and the Catalan Institute of ... new therapeutic combination to combat resistant sarcomas. The clinical ... stabilize the growth of these tumors have been published ... ., Sarcomas , Sarcomas are a rare type ... It can affect from children to older ages. It ...
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3
... other organizations must intensify efforts to improve the health ... where the lion,s share of deaths occur, says Dr. ... & gynecology. Baker is the lead author on a ... the world,s leading medical experts on women and children,s ...
... study appearing in the journal PLoS ONE, ... mathematical patterns underlying the way individuals unconsciously distribute ... their environment. These patterns appear to meet ... is a scientific law and, if confirmed in ...
... study shows , WEDNESDAY, May 26 (HealthDay News) - A ... is no longer so deadly, thanks to new technologies and ... researchers report. , A study in the May 27 issue ... the effectiveness of older and newer versions of devices aimed ...
... right thing, researcher says , WEDNESDAY, May 26 (HealthDay News) ... open the door for manufacturers and restaurants to add other ... study finds. , A team from Harvard School of Public ... found little cause for alarm. , "We found that in ...
... of Medicine of the National Academies will convene a ... Illinois at Chicago to discuss the rapidly rising rates ... UIC Midwest Conference on Diabetes and Obesity will bring ... Causes, treatment, preventive measures and policy issues will be ...
... analyzing 2.5 million screening mammograms performed on nearly one ... improved over a nine-year period. Results of the study ... Radiology . "To our knowledge, this is ... in a large representative sample of women undergoing screening ...
Cached Medicine News:Health News:Study finds 'law-like' patterns in human preference behavior 2Health News:Study finds 'law-like' patterns in human preference behavior 3Health News:Progress Made Against Once-Fatal Heart Defect 2Health News:Progress Made Against Once-Fatal Heart Defect 3Health News:Healthier Fats Replacing Trans Fats, Study Finds 2Health News:Healthier Fats Replacing Trans Fats, Study Finds 3Health News:UIC to host Institute of Medicine Meeting on diabetes and obesity 2Health News:Detection of breast cancer in screening mammography has improved over time 2
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 7, 2011 In an address to ... John C. Lechleiter, Ph.D., chairman, president and chief executive ... build a new level of trust between the biopharmaceutical ... can harness innovation to help meet growing health care ...
... 2011 Merit Medical Systems, Inc. (NASDAQ: MMSI ... used primarily in cardiology, radiology and endoscopy, announced today that ... quarter ended June 30, 2011, after the close of the ... will hold its investor conference call on the same day ...
Cached Medicine Technology:Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 2Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 3Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 4
Interphlex Flexible Stablization Rods offer correction of Hammer Toes with a High level of Flexibility while maintaining correct toe length and shape....
The Continuous Wave II Arthroscopy Pump provides pulse-free, continuous fluid inflow for joint distention when used in conjunction with a high flow sheath or separate inflow cannula....
True/Fix Distal Femoral Nail System...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
Medicine Products: